Literature DB >> 1489207

Occurrence of the nfxB type mutation in clinical isolates of Pseudomonas aeruginosa.

E B Jakics1, S Iyobe, K Hirai, H Fukuda, H Hashimoto.   

Abstract

Seven spontaneous norfloxacin (NFLX)-resistant mutants obtained in vitro from 20 NFLX-susceptible clinical isolates and 3 NFLX-resistant clinical isolates of Pseudomonas aeruginosa were transformed with the pNF111 plasmid, whose BamHI fragment is responsible for conferring susceptibility to NFLX, by complementing the nfxB mutation. The resulting patterns of MICs of NFLX, beta-lactams, aminoglycosides, and chloramphenicol and the observed increased accumulation of NFLX were consistent with the occurrence of the nfxB type mutation in these clinical isolates.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1489207      PMCID: PMC284377          DOI: 10.1128/AAC.36.11.2562

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  15 in total

1.  In vitro activity of ciprofloxacin in combination with ceftazidime, aztreonam, and azlocillin against multiresistant isolates of Pseudomonas aeruginosa.

Authors:  C I Bustamante; R C Wharton; J C Wade
Journal:  Antimicrob Agents Chemother       Date:  1990-09       Impact factor: 5.191

Review 2.  Drug resistance of Pseudomonas aeruginosa with special reference to new quinolones.

Authors:  S Iyobe; K Hirai; H Hashimoto
Journal:  Antibiot Chemother (1971)       Date:  1991

3.  Cloning and characterization of a DNA fragment that complements the nfxB mutation in Pseudomonas aeruginosa PAO.

Authors:  T Okazaki; S Iyobe; H Hashimoto; K Hirai
Journal:  FEMS Microbiol Lett       Date:  1991-03-15       Impact factor: 2.742

4.  Apparent absence of transferable resistance to nalidixic acid in pathogenic Gram-negative bacteria.

Authors:  L G Burman
Journal:  J Antimicrob Chemother       Date:  1977-09       Impact factor: 5.790

5.  New norfloxacin resistance gene in Pseudomonas aeruginosa PAO.

Authors:  H Fukuda; M Hosaka; K Hirai; S Iyobe
Journal:  Antimicrob Agents Chemother       Date:  1990-09       Impact factor: 5.191

6.  Comparative in vitro activity of cefepime (BMY 28142) against multiresistant nosocomial isolates of Pseudomonas aeruginosa.

Authors:  D Voutsinas; T Mavroudis; A Avlamis; H Giamarellou
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-10       Impact factor: 3.267

7.  Resistance of Pseudomonas aeruginosa PAO to nalidixic acid and low levels of beta-lactam antibiotics: mapping of chromosomal genes.

Authors:  M Rella; D Haas
Journal:  Antimicrob Agents Chemother       Date:  1982-08       Impact factor: 5.191

Review 8.  Bacterial resistance to fluoroquinolones.

Authors:  H C Neu
Journal:  Rev Infect Dis       Date:  1988 Jan-Feb

9.  Plasmid-mediated gentamicin resistance of Pseudomonas aeruginosa and its lack of expression in Escherichia coli.

Authors:  T Kato; Y Sato; S Iyobe; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1982-09       Impact factor: 5.191

10.  Low cost device for electrotransformation and its application to the highly efficient transformation of Escherichia coli and Enterococcus faecalis.

Authors:  S Fujimoto; H Hashimoto; Y Ike
Journal:  Plasmid       Date:  1991-09       Impact factor: 3.466

View more
  21 in total

Review 1.  Efflux-mediated resistance to fluoroquinolones in gram-negative bacteria.

Authors:  K Poole
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

2.  Type II topoisomerase mutations in ciprofloxacin-resistant strains of Pseudomonas aeruginosa.

Authors:  H Mouneimné; J Robert; V Jarlier; E Cambau
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

3.  A dose-response study of antibiotic resistance in Pseudomonas aeruginosa biofilms.

Authors:  A Brooun; S Liu; K Lewis
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

4.  Molecular mechanisms of fluoroquinolone resistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.

Authors:  S Jalal; O Ciofu; N Hoiby; N Gotoh; B Wretlind
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

5.  Involvement of an active efflux system in the natural resistance of Pseudomonas aeruginosa to aminoglycosides.

Authors:  J R Aires; T Köhler; H Nikaido; P Plésiat
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

6.  Overexpression of MexCD-OprJ reduces Pseudomonas aeruginosa virulence by increasing its susceptibility to complement-mediated killing.

Authors:  Inmaculada Martínez-Ramos; Xavier Mulet; Bartolomé Moyá; Mariette Barbier; Antonio Oliver; Sebastián Albertí
Journal:  Antimicrob Agents Chemother       Date:  2014-01-13       Impact factor: 5.191

7.  Differential selection of multidrug efflux systems by quinolones in Pseudomonas aeruginosa.

Authors:  T Köhler; M Michea-Hamzehpour; P Plesiat; A L Kahr; J C Pechere
Journal:  Antimicrob Agents Chemother       Date:  1997-11       Impact factor: 5.191

8.  Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.

Authors:  Xavier Mulet; María D Maciá; Ana Mena; Carlos Juan; José L Pérez; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2009-02-02       Impact factor: 5.191

9.  Mechanisms of high-level resistance to quinolones in urinary tract isolates of Pseudomonas aeruginosa.

Authors:  T Yoshida; T Muratani; S Iyobe; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1994-07       Impact factor: 5.191

10.  Resistance and virulence of Pseudomonas aeruginosa clinical strains overproducing the MexCD-OprJ efflux pump.

Authors:  Katy Jeannot; Sylvie Elsen; Thilo Köhler; Ina Attree; Christian van Delden; Patrick Plésiat
Journal:  Antimicrob Agents Chemother       Date:  2008-05-12       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.